Загрузка...
Data from the US and UK cystic fibrosis registries support disease modification by CFTR modulation with ivacaftor
BACKGROUND: Ivacaftor is the first cystic fibrosis transmembrane conductance regulator (CFTR) modulator demonstrating clinical benefit in patients with cystic fibrosis (CF). As ivacaftor is intended for chronic, lifelong use, understanding long-term effects is important for patients and healthcare p...
Сохранить в:
| Опубликовано в: : | Thorax |
|---|---|
| Главные авторы: | , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group
2018
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6204955/ https://ncbi.nlm.nih.gov/pubmed/29748252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/thoraxjnl-2017-210394 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|